Cargando…
Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review
OBJECTIVES: To summarize cost-effectiveness (CE) evidence of sacubitril/valsartan for the treatment of heart failure (HF) patients with reduced ejection fraction (HFrEF). The impact of different modeling approaches and parameters on the CE results is also described. METHODS: We conducted a systemati...
Autores principales: | Proudfoot, Clare, Gautam, Raju, Cristino, Joaquim, Agrawal, Rumjhum, Thakur, Lalit, Tolley, Keith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060315/ https://www.ncbi.nlm.nih.gov/pubmed/35790595 http://dx.doi.org/10.1007/s10198-022-01485-3 |
Ejemplares similares
-
Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
por: Shore, Supriya, et al.
Publicado: (2022) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018) -
Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)